Published in Mol Pharm on October 05, 2009
Crystal structure of a bacterial homologue of the bile acid sodium symporter ASBT. Nature (2011) 1.72
Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res (2012) 1.15
Role of the intestinal bile acid transporters in bile acid and drug disposition. Handb Exp Pharmacol (2011) 1.14
The solute carrier family 10 (SLC10): beyond bile acid transport. Mol Aspects Med (2013) 1.11
SLC transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov (2015) 1.02
Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol Pharm (2013) 0.99
A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus. F1000Res (2014) 0.99
Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters. Pflugers Arch (2013) 0.97
Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis. Pharm Res (2012) 0.94
An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. J Pharm Sci (2013) 0.89
Machine learning models identify molecules active against the Ebola virus in vitro. F1000Res (2015) 0.85
Molecular analysis and structure-activity relationship modeling of the substrate/inhibitor interaction site of plasma membrane monoamine transporter. J Pharmacol Exp Ther (2011) 0.85
Design and characterization of a novel fluorinated magnetic resonance imaging agent for functional analysis of bile Acid transporter activity. Pharm Res (2013) 0.84
Computational modeling to accelerate the identification of substrates and inhibitors for transporters that affect drug disposition. Clin Pharmacol Ther (2012) 0.84
Reliability of inhibition models to correctly identify type of inhibition. Pharm Res (2010) 0.84
Identification of inhibitor concentrations to efficiently screen and measure inhibition Ki values against solute carrier transporters. Eur J Pharm Sci (2010) 0.84
In vivo magnetic resonance imaging to detect biliary excretion of 19F-labeled drug in mice. Drug Metab Dispos (2011) 0.83
Why we should be vigilant: drug cytotoxicity observed with in vitro transporter inhibition studies. Biochem Pharmacol (2010) 0.83
A substrate pharmacophore for the human organic cation/carnitine transporter identifies compounds associated with rhabdomyolysis. Mol Pharm (2012) 0.82
Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery. PLoS Negl Trop Dis (2015) 0.81
Making Transporter Models for Drug-Drug Interaction Prediction Mobile. Drug Metab Dispos (2015) 0.78
Synthesis and in vitro evaluation of potential sustained release prodrugs via targeting ASBT. Int J Pharm (2010) 0.78
Open Source Bayesian Models. 3. Composite Models for Prediction of Binned Responses. J Chem Inf Model (2016) 0.78
Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids. Carcinogenesis (2015) 0.78
Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Models for Mycobacterium tuberculosis Drug Discovery. PLoS One (2015) 0.76
Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport. J Vis Exp (2016) 0.75
The Next Era: Deep Learning in Pharmaceutical Research. Pharm Res (2016) 0.75
Calcium-channel blockade and incidence of cancer in aged populations. Lancet (1996) 8.04
Statins and the risk of colorectal cancer. N Engl J Med (2005) 6.86
Cheminformatics analysis and learning in a data pipelining environment. Mol Divers (2006) 3.86
Cancer risk in users of calcium channel blockers. Hypertension (1997) 3.30
Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology (2003) 3.22
Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of N-methyl-N'-nitro-N-nitrosoguanidine in rats. J Natl Cancer Inst (1974) 2.79
Faecal bile-acids and clostridia in patients with cancer of the large bowel. Lancet (1975) 2.40
Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem (2007) 2.36
Bile acid transporters. J Lipid Res (2009) 2.31
Using extended-connectivity fingerprints with Laplacian-modified Bayesian analysis in high-throughput screening follow-up. J Biomol Screen (2005) 2.05
Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer (1977) 2.03
Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J Chem Inf Model (2006) 1.95
Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J Clin Invest (1997) 1.75
Role of bile acids in colorectal carcinogenesis. Eur J Cancer (1995) 1.66
Promoting effect of sodium deoxycholate on colon adenocarcinomas in germfree rats. J Natl Cancer Inst (1976) 1.52
Calcium-channel blockers and risk of cancer. Lancet (1997) 1.46
Identification of a mutation in the ileal sodium-dependent bile acid transporter gene that abolishes transport activity. J Biol Chem (1995) 1.42
Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT). Pharm Res (2005) 1.38
Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes. Hepatology (2005) 1.38
Cancer risk and mortality in users of calcium channel blockers. A cohort study. Cancer (2000) 1.36
In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Pharm Res (2005) 1.30
Statin use and risk of colorectal cancer. J Natl Cancer Inst (2007) 1.29
Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res (1994) 1.25
Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models. J Med Chem (2002) 1.24
Bile acid transporters. Curr Opin Lipidol (1995) 1.24
Absence of dysfunctional ileal sodium-bile acid cotransporter gene mutations in patients with adult-onset idiopathic bile acid malabsorption. Scand J Gastroenterol (2001) 1.20
Activation and role of mitogen-activated protein kinases in deoxycholic acid-induced apoptosis. Carcinogenesis (2001) 1.19
Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology (2007) 1.18
The role of bile acids in carcinogenesis. Mutat Res (2001) 1.17
Recent advances in comparative molecular field analysis (CoMFA). Prog Clin Biol Res (1989) 1.17
Intestinal bile acid transport: biology, physiology, and pathophysiology. J Pediatr Gastroenterol Nutr (2001) 1.16
Substrate specificity of the ileal and the hepatic Na(+)/bile acid cotransporters of the rabbit. II. A reliable 3D QSAR pharmacophore model for the ileal Na(+)/bile acid cotransporter. J Lipid Res (1999) 1.13
Global Bayesian models for the prioritization of antitubercular agents. J Chem Inf Model (2008) 1.12
Bias in estimation of transporter kinetic parameters from overexpression systems: Interplay of transporter expression level and substrate affinity. J Pharmacol Exp Ther (2006) 1.10
Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J Biol Chem (1998) 1.05
Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups. J Comput Aided Mol Des (2007) 0.99
Improved naïve Bayesian modeling of numerical data for absorption, distribution, metabolism and excretion (ADME) property prediction. J Chem Inf Model (2006) 0.99
SC-435, an ileal apical sodium co-dependent bile acid transporter (ASBT) inhibitor lowers plasma cholesterol and reduces atherosclerosis in guinea pigs. Atherosclerosis (2003) 0.99
Diminished gene expression of ileal apical sodium bile acid transporter explains impaired absorption of bile acid in patients with hypertriglyceridemia. J Lipid Res (2000) 0.99
Drug-induced diarrhoea. Drug Saf (2000) 0.99
Molecular modeling of the intestinal bile acid carrier: a comparative molecular field analysis study. J Comput Aided Mol Des (1997) 0.97
Novel non-systemic inhibitor of ileal apical Na+-dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys. Eur J Pharmacol (2006) 0.96
Apical sodium bile acid transporter and ileal lipid binding protein in gallstone carriers. J Lipid Res (2005) 0.96
Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol Drug Saf (2008) 0.95
Deoxycholic acid activates protein kinase C and phospholipase C via increased Ca2+ entry at plasma membrane. Gastroenterology (2005) 0.94
Deoxycholyltaurine rescues human colon cancer cells from apoptosis by activating EGFR-dependent PI3K/Akt signaling. J Cell Physiol (2008) 0.93
Bile acids and colorectal cancer: hypothesis. Eur J Cancer Prev (1991) 0.92
Localization of the ileal sodium-bile acid cotransporter gene (SLC10A2) to human chromosome 13q33. Genomics (1996) 0.92
Abnormal bile acid absorption in familial hypertriglyceridemia. J Lipid Res (1995) 0.92
Pharmacophores incorporating numerous excluded volumes defined by X-ray crystallographic structure in three-dimensional database searching: application to the thyroid hormone receptor. J Med Chem (1998) 0.92
Using pharmacophore models to gain insight into structural binding and virtual screening: an application study with CDK2 and human DHFR. J Chem Inf Model (2006) 0.91
Analysis of the ileal bile acid transporter gene, SLC10A2, in subjects with familial hypertriglyceridemia. Arterioscler Thromb Vasc Biol (2001) 0.90
Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 1). J Med Chem (2005) 0.89
An association between genetic polymorphisms in the ileal sodium-dependent bile acid transporter gene and the risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev (2001) 0.88
Effects of 2164U90 on ileal bile acid absorption and serum cholesterol in rats and mice. J Lipid Res (1995) 0.87
Drug-induced diarrhea. Curr Gastroenterol Rep (2007) 0.86
Mechanism of hypocholesterolemic action of S-8921 in rats: S-8921 inhibits ileal bile acid absorption. J Pharmacol Exp Ther (1998) 0.86
Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats. Jpn J Cancer Res (1998) 0.86
Non-steroidal anti-inflammatory drugs and statins in relation to colorectal cancer risk. World J Gastroenterol (2009) 0.85
Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 2). J Med Chem (2005) 0.84
Calcium channel blockers: spectrum of side effects and drug interactions. Acta Pharmacol Toxicol (Copenh) (1986) 0.83
Effects of common haplotypes of the ileal sodium dependent bile acid transporter gene on the development of sporadic and familial colorectal cancer: a case control study. BMC Med Genet (2008) 0.81
New insights into bile acid transport. Curr Opin Lipidol (1998) 0.80
Inhibition of ileal sodium-dependent bile acid transport by 2164U90. J Lipid Res (1995) 0.80
Statins and the risk of colorectal cancer. N Engl J Med (2005) 0.79
Is the use of some calcium antagonists linked to cancer? Evidence from recent observational studies. Drugs Aging (1998) 0.78
Effect of the dimeric bile acid analogue S 0960, a specific inhibitor of the apical sodium-dependent bile salt transporter in the ileum, on the renal handling of taurocholate. Arzneimittelforschung (2003) 0.78
Refinement of Catalyst hypotheses using simplex optimisation. J Comput Aided Mol Des (2000) 0.78
Use of calcium channel blockers as antihypertensives in relation to mortality and cancer incidence: a population-based observational study. Pharmacoepidemiol Drug Saf (2002) 0.78
Antihypertensive drugs and risk of malignant diseases. Lancet (1996) 0.77
Effect of olsalazine on sodium-dependent bile acid transport in rat ileum. Dig Dis Sci (1995) 0.77
A novel class of apical sodium co-dependent bile acid transporter inhibitors: the 2,3-disubstituted-4-phenylquinolines. Bioorg Med Chem Lett (2000) 0.77
Is the use of antihypertensives and sedatives a major risk factor for colorectal cancer? Scand J Gastroenterol (1993) 0.77
Faecal bile acids and bowel cancer risk in gastric-surgery patients. Eur J Cancer Prev (1991) 0.77
[Chronic diarrhea caused by isradipine]. Gastroenterol Clin Biol (1993) 0.77
Calcium antagonists and cancer: causation or association? Cardiovasc Drugs Ther (1998) 0.76
[Hypolipidemic drugs--ileal Na+/bile acid cotransporter inhibitors (S-8921 etc)]. Nihon Rinsho (2002) 0.76
Statins and cancer: will we ever know the answer? Epidemiology (2002) 0.76
Quality assessment of colonoscopic cecal intubation: an analysis of 6 years of continuous practice at a university hospital. Am J Gastroenterol (2006) 3.49
Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res (2002) 1.74
A novel method for generation of signature networks as biomarkers from complex high throughput data. Toxicol Lett (2005) 1.71
Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos (2006) 1.68
The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res (2008) 1.57
Lack of medication dose uniformity in commonly split tablets. J Am Pharm Assoc (Wash) (2002) 1.46
Bile acid-induced proliferation of a human colon cancer cell line is mediated by transactivation of epidermal growth factor receptors. Biochem Pharmacol (2005) 1.44
Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci (2002) 1.43
Muscarinic receptors and ligands in cancer. Am J Physiol Cell Physiol (2008) 1.42
Comments on effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR food evaluation study. Curr Med Res Opin (2002) 1.41
Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery. Drug Discov Today (2009) 1.40
Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation. Drug Discov Today (2012) 1.39
Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT). Pharm Res (2005) 1.38
Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Mol Pharm (2006) 1.38
Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem (2008) 1.37
Human cecal bile acids: concentration and spectrum. Am J Physiol Gastrointest Liver Physiol (2007) 1.35
Increased acyclovir oral bioavailability via a bile acid conjugate. Mol Pharm (2004) 1.32
Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell line. Biochem Pharmacol (2006) 1.30
Transactivation of the epidermal growth factor receptor mediates cholinergic agonist-induced proliferation of H508 human colon cancer cells. Cancer Res (2003) 1.28
Mobile apps for chemistry in the world of drug discovery. Drug Discov Today (2011) 1.26
Interaction of native bile acids with human apical sodium-dependent bile acid transporter (hASBT): influence of steroidal hydroxylation pattern and C-24 conjugation. Pharm Res (2006) 1.25
Methods for predicting human drug metabolism. Adv Clin Chem (2007) 1.24
A quality alert and call for improved curation of public chemistry databases. Drug Discov Today (2011) 1.22
Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol Pharmacol (2005) 1.21
New predictive models for blood-brain barrier permeability of drug-like molecules. Pharm Res (2008) 1.20
Acetylcholine-induced activation of M3 muscarinic receptors stimulates robust matrix metalloproteinase gene expression in human colon cancer cells. Am J Physiol Gastrointest Liver Physiol (2009) 1.19
Acetylcholine release by human colon cancer cells mediates autocrine stimulation of cell proliferation. Am J Physiol Gastrointest Liver Physiol (2008) 1.19
The importance of discerning shape in molecular pharmacology. Trends Pharmacol Sci (2009) 1.17
A generalizable pre-clinical research approach for orphan disease therapy. Orphanet J Rare Dis (2012) 1.16
Pharmacophore-based discovery of ligands for drug transporters. Adv Drug Deliv Rev (2006) 1.15
Reaching out to collaborators: crowdsourcing for pharmaceutical research. Pharm Res (2010) 1.14
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos (2008) 1.14
Bacterial peptide recognition and immune activation facilitated by human peptide transporter PEPT2. Am J Respir Cell Mol Biol (2008) 1.13
Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. BMC Emerg Med (2009) 1.12
The solute carrier family 10 (SLC10): beyond bile acid transport. Mol Aspects Med (2013) 1.11
Meeting report: applied biopharmaceutics and quality by design for dissolution/release specification setting: product quality for patient benefit. AAPS J (2010) 1.11
Bias in estimation of transporter kinetic parameters from overexpression systems: Interplay of transporter expression level and substrate affinity. J Pharmacol Exp Ther (2006) 1.10
Impact of Biopharmaceutics Classification System-based biowaivers. Mol Pharm (2010) 1.09
Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing. Pharm Res (2009) 1.09
Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists. Pharm Res (2009) 1.09
Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol (2003) 1.08
Evolution of the bile salt nuclear receptor FXR in vertebrates. J Lipid Res (2008) 1.08
Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K. J Pharmacol Exp Ther (2012) 1.07
3',5'-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation. Biochem Biophys Res Commun (2005) 1.07
Molecular switch controlling the binding of anionic bile acid conjugates to human apical sodium-dependent bile acid transporter. J Med Chem (2010) 1.07
Functional interaction of lithocholic acid conjugates with M3 muscarinic receptors on a human colon cancer cell line. Biochim Biophys Acta (2002) 1.07
Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery. Drug Discov Today (2013) 1.07
Ligand specificity and evolution of liver X receptors. J Steroid Biochem Mol Biol (2008) 1.06
Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates. Drug Discov Today (2012) 1.05
Chemical target and pathway toxicity mechanisms defined in primary human cell systems. J Pharmacol Toxicol Methods (2009) 1.04
Using open source computational tools for predicting human metabolic stability and additional absorption, distribution, metabolism, excretion, and toxicity properties. Drug Metab Dispos (2010) 1.04
Essential metabolites of Mycobacterium tuberculosis and their mimics. MBio (2011) 1.04
Time for cooperation in health economics among the modelling community. Pharmacoeconomics (2010) 1.04
Influence of charge and steric bulk in the C-24 region on the interaction of bile acids with human apical sodium-dependent bile acid transporter. Mol Pharm (2006) 1.03
Structural determinants for transport across the intestinal bile acid transporter using C-24 bile acid conjugates. Mol Pharm (2010) 1.01
Muscarinic receptor agonists stimulate human colon cancer cell migration and invasion. Am J Physiol Gastrointest Liver Physiol (2011) 1.01
Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther (2005) 1.01
Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem Res Toxicol (2008) 1.01
Method to screen substrates of apical sodium-dependent bile acid transporter. AAPS J (2008) 1.00
Akt-dependent NF-kappaB activation is required for bile acids to rescue colon cancer cells from stress-induced apoptosis. Exp Cell Res (2008) 1.00
Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol Pharm (2013) 0.99
Machine learning methods and docking for predicting human pregnane X receptor activation. Chem Res Toxicol (2008) 0.99
PXR and the regulation of apoA1 and HDL-cholesterol in rodents. Pharmacol Res (2004) 0.98
Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Mol Cell Endocrinol (2010) 0.97
Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. Curr Comput Aided Drug Des (2011) 0.97
Parallel worlds of public and commercial bioactive chemistry data. J Med Chem (2014) 0.97
Structural biology and function of solute transporters: implications for identifying and designing substrates. Drug Metab Rev (2002) 0.97
Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab Dispos (2007) 0.96
Vasodilatory effects of cholinergic agonists are greatly diminished in aorta from M3R-/- mice. Eur J Pharmacol (2004) 0.96
Redefining Cheminformatics with Intuitive Collaborative Mobile Apps. Mol Inform (2012) 0.96
Comprehensive computational assessment of ADME properties using mapping techniques. Curr Drug Discov Technol (2005) 0.95
Bile acids regulate cardiovascular function. Clin Transl Sci (2011) 0.95
Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. Am J Physiol Gastrointest Liver Physiol (2012) 0.94
Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis. Pharm Res (2012) 0.94
Computational models to assign biopharmaceutics drug disposition classification from molecular structure. Pharm Res (2007) 0.94
Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity. J Pharm Sci (2004) 0.94
Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR. J Biol Chem (2013) 0.93
Discovery of novel antimalarial compounds enabled by QSAR-based virtual screening. J Chem Inf Model (2013) 0.93
Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition. Chem Res Toxicol (2010) 0.93
Intrinsic disorder in nuclear hormone receptors. J Proteome Res (2008) 0.92
Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos (2010) 0.92
Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50). J Biomol Screen (2002) 0.91
Cholinergic agonist-induced pepsinogen secretion from murine gastric chief cells is mediated by M1 and M3 muscarinic receptors. Am J Physiol Gastrointest Liver Physiol (2005) 0.91
Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). Toxicol Appl Pharmacol (2013) 0.91
Pharmacophore modeling of cytochromes P450. Adv Drug Deliv Rev (2002) 0.90
Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups. Eur J Pharm Sci (2012) 0.90
Reengineering the pharmaceutical industry by crash-testing molecules. Drug Discov Today (2005) 0.90
Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res (2006) 0.90
Quantitative structure activity relationship for inhibition of human organic cation/carnitine transporter. Mol Pharm (2010) 0.90
Impact of impurity on kinetic estimates from transport and inhibition studies. J Pharmacol Exp Ther (2008) 0.90
Deoxycholyltaurine-induced vasodilation of rodent aorta is nitric oxide- and muscarinic M(3) receptor-dependent. Eur J Pharmacol (2005) 0.89
Computational models for neglected diseases: gaps and opportunities. Pharm Res (2013) 0.89
Inhibition requirements of the human apical sodium-dependent bile acid transporter (hASBT) using aminopiperidine conjugates of glutamyl-bile acids. Pharm Res (2009) 0.89
In vivo performance of a novel fluorinated magnetic resonance imaging agent for functional analysis of bile acid transport. Mol Pharm (2014) 0.89
Troubleshooting computational methods in drug discovery. J Pharmacol Toxicol Methods (2010) 0.89